Please login to the form below

Not currently logged in
Email:
Password:

NHS England

This page shows the latest NHS England news and features for those working in and with pharma, biotech and healthcare.

Takeda’s HAE drug Takhzyro backed by NICE

Takeda’s HAE drug Takhzyro backed by NICE

New treatment option for rare, hereditary disease. Takeda’s drug for the rare disease hereditary angioedema (HAE) should be made available routinely on the NHS in England and Wales, says NICE. ... We hope the NHS and healthcare professionals will

Latest news

  • Vertex scores CF deal with Scotland, but access debate continues Vertex scores CF deal with Scotland, but access debate continues

    The NHS in England offered £500m over five years and £1bn over ten years for access to all of Vertex’s CF drugs, but this was rejected by the pharma company. ... However, Vertex said it had already offered England its lowest (confidential) price

  • Novartis’ CAR-T Kymriah scores SMC approval Novartis’ CAR-T Kymriah scores SMC approval

    The Swiss pharma then struck a deal with  NHS England, which came just ten days after the European approval. ... Gilead faced an  initial hurdle when initially NICE rejected the use of its CAR-T therapy, but later  reached an agreement with NHS

  • NICE backs NHS use of Novartis’ gene therapy Luxturna NICE backs NHS use of Novartis’ gene therapy Luxturna

    According to the draft guidance, the company and NHS England have agreed a confidential discount on the list price of £613, 410 for the therapy. ... Through effective collaboration with NICE and NHS England, it has been possible to secure rapid access

  • NICE’s long-serving chief exec Sir Andrew Dillon to step down NICE’s long-serving chief exec Sir Andrew Dillon to step down

    This included at one time plans to strip its guidance of its mandatory status for the NHS, but its role in England’s NHS is now assured. ... The last two years has seen controversy ease somewhat for NICE, as NHS England has played an increasingly

  • Roche’s Hemlibra scores broader NHS funding Roche’s Hemlibra scores broader NHS funding

    The market access agreement in England has been achieved once again via direct pricing and access negotiations with budget holder NHS England, with NICE not involved at all. ... NHS England will have undoubtedly driven a hard bargain during confidential

More from news
Approximately 67 fully matching, plus 445 partially matching documents found.

Latest Intelligence

  • The Cystic Fibrosis Buyers’ Club The Cystic Fibrosis Buyers’ Club

    Orkambi is currently out of reach because of a three-year-long dispute between manufacturer Vertex and NHS England, which shows little sign of ending any time soon. ... Gador. As of early July 2019, McDonald said: “Patients are liaising with their NHS

  • 25 Women Leaders in UK Healthcare 25 Women Leaders in UK Healthcare

    3. DR RUTH MAY. Nurse leader. Ruth is the chief nursing officer for England and an executive/national director at NHS England and NHS Improvement. ... NHS England is now aiming to recruit an extra 40, 000 nurses over the next five years.

  • 25 Women Leaders in UK Healthcare (part 2) 25 Women Leaders in UK Healthcare (part 2)

    She is director of Workforce Race Equality Standard Implementation for NHS England and deputy president of the Royal College of Nursing. ... NHS England judged Gilead’s offer to be the best, giving it a‘Gold’ partner status.

  • The UK’s new medicines pricing deal – opportunities and risks for pharma The UK’s new medicines pricing deal – opportunities and risks for pharma

    Influence of NHS England. The growing influence of NHS England (NHSE) is very evident from the outset when reading the 2014 PPRS and the 2019 VPAS side by side. ... The difficulty is in knowing whether NHSE can really deliver its side of the bargain; can

  • The Orkambi row explained The Orkambi row explained

    NHS England's Specialised commissioning head John Stewart says this was because NHSE was new then and just finding its feet. ... NHS England had seemingly had enough of being blamed for the impasse, and decided to make its offer public last summer.

More from intelligence
Approximately 4 fully matching, plus 49 partially matching documents found.

Latest appointments

More from appointments
Approximately 3 fully matching, plus 12 partially matching documents found.

Latest from PMHub

  • A uniquely English genomic medicine service

    Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist and Director of Public Health at Genomics England, to find out how the NHS is achieving this goal. ... To prepare England for precision medicine, the NHS is rolling out a genomic

  • Precision paediatrics: Treating patients with CAR-T

    As Joint Lead Healthcare Scientist for Great Ormond Street Hospital (GOSH) Children National Health Service (NHS) Foundation Trust, and Principal Clinical Scientist in the Department of Haematology, Stuart is at the ... There is clear intent at NHS

  • A new vision for tackling key illnesses

    Diabetes. The NHS plans to double the size of the NHS Diabetes Prevention Programme for type 2 diabetes. ... The NHS will also implement HPV primary screening for cervical cancer across England by 2020.

  • Spotlight on innovation at life sciences forum

    It confirms that funding for AHSNs will be guaranteed until 2023, subject to their success in spreading proven innovations across England. ... They now have funding coming from three separate sources. NHS England (NHSE) is supporting the MedTech

  • GPs will play a pivotal role in integrated care

    Primary Care Networks. The new framework, which is an agreement between NHS England and the British Medical Association’s General Practitioners Committee (GPC) in England, gives GP practices just under £1bn ... Fourteen ICSs are already up and running

More from PMHub
Approximately 1 fully matching, plus 42 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics